Skip to content
Screener

Repligen RGEN Operating Income

Operating Income at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$2.09B
Danaher logo
DanaherDHR
$1.13B+48.3%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
-$2.16M+95.6%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$34.1M+43.9%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$119.89M+19.7%
TEC
Bio-TechneTECH
$75.5M+95.0%

Other financials

Income statement

See full
Revenue$204.1M+11.9%
Gross profit$110.0M+20.7%
Net income$5.0M-66.3%
EPS (diluted)$0.09-65.4%

Balance sheet

See full
Cash & equivalents$606.8M-14.4%
Total debt$690.9M+354%
Total equity$2.1B+2.4%
Total assets$3.0B+1.7%

Cash flow

See full
Operating cash flow$32.8M+14.5%
CapEx$5.3M-24.9%
Free cash flow$27.4M+27.5%

Valuation

See full
Market cap$8.95B+42.1%
Enterprise value$9.03B+57.3%
P/E215.5×
P/S11.6×+0.3×

Profitability

See full
Gross margin47.6%+0.9pp
Operating margin15.6%-11.0pp
Net margin17.3%-3.5pp
FCF margin22%+6.9pp

Returns & leverage

See full
Return on equity2%+1.6pp
Debt / equity0.3×+0.3×
Current ratio9.1×+0.5×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Repligen’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323773
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Restructuring activities and other charges2,7182,1624,2144,135
Change in fair value of contingent consideration2,308(7,939)2,162(7,939)
Total costs and operating expenses190,152168,470368,467331,064
Income from operations13,97613,89629,91620,474
Other income (expense), net:
Investment income6,4316,58512,77313,899
Interest expense(5,663)(5,354)(11,241)(10,604)
Amortization of debt issuance costs(421)(414)(840)(827)

ITEM 1. Financial Statements

FAQ

What is Repligen's operating income?
Repligen (RGEN) reported operating income of $13.98M in Q2 2026.
How has Repligen's operating income changed year-over-year?
Repligen's operating income increased by 0.6% year-over-year, from $13.9M to $13.98M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Repligen's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude